Journal of cardiovascular electrophysiology · 2026
Utility of Very High Output Pace-Capture Testing for Posterior Wall Isolation in Patients With Persistent Atrial Fibrillation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hsia Brian, Liebman Jordan, Garber Leonid, Yang Felix, Spinelli Michael, Malyshev Yury, Kushnir Alexander, Jankelson Lior, Bernstein Scott, Park David, Barbhaiya Chirag, Holmes Douglas, Chinitz Larry A, Aizer Anthony
Аннотация
BACKGROUND: Pulmonary vein isolation (PVI) and posterior wall isolation (PWI) are frequently used in the treatment of persistent atrial fibrillation (AF). Minimal data support adjunct PWI, possibly due to lack of durability via epicardial reconnections.
OBJECTIVE: To determine the impact of very high output PW pace-capture testing in patients with persistent AF on AF/AT recurrence.
METHODS: We performed a retrospective study of consecutive patients who underwent radiofrequency ablation for persistent AF and received PVI and PWI, as well as a cavotricuspid isthmus line (CTI). After the creation of three linear PW lesions (roof, carina-to-carina, and inferior PV levels), pace-capture testing was performed on the PW. The first cohort confirmed PWI using 10 mA at 2 ms (10 × 2) to pace capture. Sequentially, the second cohort utilized 20 mA at 10 ms (20 × 10). If the PW was captured, additional lesions were performed. Patients were excluded if additional lesion sets beyond PVI, PWI, and CTI were performed.
RESULTS: A total of 232 patients were included. Of these, 129 (56%) patients were in the 20 × 10 group, and 103 (44%) patients were in the 10 × 2 group. The two groups did not differ in age, sex, proportion of comorbidities, presenting rhythm, left ventricular ejection fraction, or left atrial size. Despite the increase in procedure time and lesion number, in the time-to-event analysis, patients in the 20 × 10 group experienced recurrent AF/AT more frequently than those in the 10 × 2 group (log rank p = 0.01).
CONCLUSION: Testing PWI in persistent AF with pace capture at 20 mA at 10 ms did not improve freedom from arrhythmia and may paradoxically be associated with harm. Our findings question whether PWI, regardless of durability, is effective in treating persistent AF.
OBJECTIVE: To determine the impact of very high output PW pace-capture testing in patients with persistent AF on AF/AT recurrence.
METHODS: We performed a retrospective study of consecutive patients who underwent radiofrequency ablation for persistent AF and received PVI and PWI, as well as a cavotricuspid isthmus line (CTI). After the creation of three linear PW lesions (roof, carina-to-carina, and inferior PV levels), pace-capture testing was performed on the PW. The first cohort confirmed PWI using 10 mA at 2 ms (10 × 2) to pace capture. Sequentially, the second cohort utilized 20 mA at 10 ms (20 × 10). If the PW was captured, additional lesions were performed. Patients were excluded if additional lesion sets beyond PVI, PWI, and CTI were performed.
RESULTS: A total of 232 patients were included. Of these, 129 (56%) patients were in the 20 × 10 group, and 103 (44%) patients were in the 10 × 2 group. The two groups did not differ in age, sex, proportion of comorbidities, presenting rhythm, left ventricular ejection fraction, or left atrial size. Despite the increase in procedure time and lesion number, in the time-to-event analysis, patients in the 20 × 10 group experienced recurrent AF/AT more frequently than those in the 10 × 2 group (log rank p = 0.01).
CONCLUSION: Testing PWI in persistent AF with pace capture at 20 mA at 10 ms did not improve freedom from arrhythmia and may paradoxically be associated with harm. Our findings question whether PWI, regardless of durability, is effective in treating persistent AF.